Patient and Provider Factors Associated With Initiating Sodium-Glucose Cotransporter-2 Inhibitors (SGTL2is) Following FDA Approval for Heart Failure With Preserved and Mildly Reduced Ejection Fraction

Affiliations

• ¹ Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland, Ohio; Kaufman Center for Heart Failure Treatment and Recovery, Cleveland Clinic, Cleveland, Ohio. Electronic address: martynm2@ccf.org.
• ² Joe DiMaggio Children's Hospital Heart Institute and Memorial Cardiac and Vascular Institute, Hollywood, Florida.
• ³ Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland, Ohio.
• ⁴ Primary Care Institute, Cleveland Clinic, Cleveland, Ohio; Center for Value-Based Care Research, Cleveland Clinic, Cleveland, Ohio.
• ⁵ Primary Care Institute, Cleveland Clinic, Cleveland, Ohio.
• ⁶ Cleveland Clinic Florida, Weston, Florida.
• ⁷ Kaufman Center for Heart Failure Treatment and Recovery, Cleveland Clinic, Cleveland, Ohio; Nursing Institute, Cleveland Clinic, Cleveland, Ohio.
• ⁸ Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland, Ohio; Kaufman Center for Heart Failure Treatment and Recovery, Cleveland Clinic, Cleveland, Ohio.